Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Buggisch

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2020
Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutionsJulia Dietz, Johannes Vermehren, Katrin Matschenz, et al.
Journal of Clinical Medicine|December 8, 2019
Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV InfectionChristiana Graf, Antonia Mondorf, Viola Knop, et al.
Hepatology (Baltimore, Md.)|December 10, 2009
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analoguesFlorian van Bömmel, Robert A de Man, Heiner Wedemeyer, et al.
Gastroenterology|July 2, 2013
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infectionPatrick Marcellin, Curtis Cooper, Luis Balart, et al.
Journal of Hepatology|August 28, 2022
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failureJulia Dietz, Beat Müllhaupt, Peter Buggisch, et al.
Gastroenterology|November 18, 2017
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting AntiviralsJulia Dietz, Simone Susser, Johannes Vermehren, et al.
JHEP Reports : Innovation in Hepatology|July 15, 2024
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patientsJulia Dietz, Christiana Graf, Christoph P Berg, et al.
The American Journal of Gastroenterology|June 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study ResultsCynthia Levy, Palak J Trivedi, Kris V Kowdley, et al.
Gut|May 20, 2016
Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infectionJanett Fischer, Alexander N R Weber, Stephan Böhm, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 10, 2019
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 InfectionsJulia Dietz, Ulrich Spengler, Beat Müllhaupt, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Liver International : Official Journal of the International Association for the Study of the Liver|July 9, 2020
Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutionsJulia Dietz, Johannes Vermehren, Katrin Matschenz, et al.
Journal of Clinical Medicine|December 8, 2019
Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV InfectionChristiana Graf, Antonia Mondorf, Viola Knop, et al.
Hepatology (Baltimore, Md.)|December 10, 2009
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analoguesFlorian van Bömmel, Robert A de Man, Heiner Wedemeyer, et al.
Gastroenterology|July 2, 2013
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infectionPatrick Marcellin, Curtis Cooper, Luis Balart, et al.
Journal of Hepatology|August 28, 2022
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failureJulia Dietz, Beat Müllhaupt, Peter Buggisch, et al.
Gastroenterology|November 18, 2017
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting AntiviralsJulia Dietz, Simone Susser, Johannes Vermehren, et al.
JHEP Reports : Innovation in Hepatology|July 15, 2024
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patientsJulia Dietz, Christiana Graf, Christoph P Berg, et al.
The American Journal of Gastroenterology|June 24, 2025
Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study ResultsCynthia Levy, Palak J Trivedi, Kris V Kowdley, et al.
Gut|May 20, 2016
Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infectionJanett Fischer, Alexander N R Weber, Stephan Böhm, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 10, 2019
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 InfectionsJulia Dietz, Ulrich Spengler, Beat Müllhaupt, et al.
Pageof 11